Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 455-459

  Pagani, Olivia ^a,b   Gelber, Shari ^c   Colleoni, Marco ^d   Price, Karen N ^c   Simoncini, Edda ^e  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e Breast Unit Dipartimento di Oncologia Azienda Spedali Civili di Brescia   (Italy)

Author keywords

Breast cancer; Endocrine treatment; Selective estrogen receptor modulators; Tamoxifen; Toremifene; Treatment adherence

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; PATIENT COMPLIANCE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 84890430455     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2757-x     Document Type: Article

References (32)

1. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515-1524
2. Partridge AH, Wang PS, Winer EP et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606
3. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1-9
4. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44-47
5. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497
6. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868-2879
7. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 16(2):CD000011
8. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661
9. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66
10. Barron TI, Connolly R, Bennett K et al (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832-839
11. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor positive breast cancer. J Clin Oncol 26:549-555
12. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328
13. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130:681-689
14. Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220
15. Kahn KL, Schneider EC, Malin JL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431-439
16. Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271-2276
17. Fallowfield L, Atkins L, Catt S et al (2006) Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205-210
18. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128
19. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189-1197
20. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436
21. Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191-200
22. Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562
23. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
24. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
25. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537
26. Verma S, Madarnas Y, Sehdev S, Martin G, Bajcar J (2011) Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Curr Oncol 18(Suppl 1):S3-S9
27. Goss PE, Ingle JN, Pater JL et al (2008) Late extended adjuvant treatment with letrozole improved outcome in women with early stage breast cancer who completes 5 years of tamoxifen. J Clin Oncol 26:1948-1955
28. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542
29. International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A et al (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. J Clin Oncol 24:1332-1341
30. Anderson JR, Cain KC, Gelber RD, Gelman RS (1985) Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep 69:1139-1146
31. Davies C, Pan H, Goodwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816
32. Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer. J Clin Oncol 31(suppl; abstr 5)